Brighten Your Day

Doctor Is Still Cancer-Free After Incurable Brain Tumor Diagnosis, Thanks To His Own Treatment

May 16, 2024

Today's good news story comes from Sydney, Australia.

Australian doctor Professor Richard Scolyer has announced that he remains cancer-free one year after undergoing a pioneering treatment for glioblastoma (GBM), one of the most aggressive and deadly forms of brain cancer.

The 57-year-old professor's latest MRI scan confirmed no recurrence of the tumor, marking a significant milestone in the fight against GBM.

Credit: Professor Richard Scolyer AO / @ProfRScolyerMIA

Dr. Scolyer, renowned for his groundbreaking research on melanoma, was diagnosed with a particularly aggressive subtype of GBM in June last year following a seizure while in Poland. GBM typically has a dire prognosis, with most patients surviving less than a year after diagnosis. However, Scolyer's experience has defied these odds, offering new hope to patients worldwide.

Sharing his joy on social media, Scolyer tweeted, "I had brain #MRI scan last Thursday looking for recurrent #glioblastoma (&/or treatment complications). I found out yesterday that there is still no sign of recurrence. I couldn’t be happier!"

I had brain #MRI scan last Thursday looking for recurrent #glioblastoma (&/or treatment complications). I found out yesterday that there is still no sign of recurrence. I couldn’t be happier!!!!!

Thank you to the fabulous team looking after me so well especially my wife Katie &… pic.twitter.com/WdqZKLDvge

— Professor Richard Scolyer AO (@ProfRScolyerMIA) May 13, 2024

Scolyer's treatment was a world-first, involving pre-surgery combination immunotherapy. Leveraging his extensive knowledge and research on melanoma, he applied this innovative approach to his own condition. This novel treatment strategy aimed to activate the immune system to fight the cancer more effectively.

"We've shown that you can activate the immune system and do it very well. This is now a foundational first step to change the field and the way drugs are explored in brain cancer," Scolyer told Sky News.